Venetoclax for AML: changing the treatment paradigm
Daniel A. Pollyea(University of Colorado Denver), Marina Konopleva(The University of Texas MD Anderson Cancer Center)
Cited by 172
Related Papers
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
|Blood|2008|512
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
|Molecular Cancer Therapeutics|2008|204
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
|Oncotarget|2016|188
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
|Signal Transduction and Targeted Therapy|2022|177